Changes in gene expression contribute to cancer prevention by COX inhibitors.
about
Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrenceNAG-1/GDF15 accumulates in the nucleus and modulates transcriptional regulation of the Smad pathwayTolfenamic acid induces apoptosis and growth inhibition in head and neck cancer: involvement of NAG-1 expressionAdaptive induction of growth differentiation factor 15 attenuates endothelial cell apoptosis in response to high glucose stimulusNSAID-activated gene-1 as a molecular target for capsaicin-induced apoptosis through a novel molecular mechanism involving GSK3beta, C/EBPbeta and ATF3.Molecular targets of apigenin in colorectal cancer cells: involvement of p21, NAG-1 and p53.The cyclooxygenase inhibitor sulindac sulfide inhibits EP4 expression and suppresses the growth of glioblastoma cells.DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell linesDamnacanthal, a noni component, exhibits antitumorigenic activity in human colorectal cancer cellsAnti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell lineBerberine, a natural isoquinoline alkaloid, induces NAG-1 and ATF3 expression in human colorectal cancer cells.Molecular characterisation of canine nonsteroidal anti-inflammatory drug-activated gene (NAG-1).What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis?Proteasome inhibitor MG132 induces NAG-1/GDF15 expression through the p38 MAPK pathway in glioblastoma cellsA reciprocal relationship exists between non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) and cyclooxygenase-2COX inhibitors directly alter gene expression: role in cancer prevention?Regulation of EP4 expression via the Sp-1 transcription factor: inhibition of expression by anti-cancer agentsNAG-1/GDF15 transgenic mouse has less white adipose tissue and a reduced inflammatory response.Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapyNonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin AEffect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells.Nonsteroidal anti-inflammatory drug-activated gene-1 expression inhibits urethane-induced pulmonary tumorigenesis in transgenic mice.Nonsteroidal anti-inflammatory drug sulindac sulfide suppresses structural protein Nesprin-2 expression in colorectal cancer cellsReview paper: Cancer chemopreventive compounds and canine cancer.The role of NAG-1/GDF15 in the inhibition of intestinal polyps in APC/Min mice by sulindacRole of TLR2-dependent inflammation in metastatic progression.The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies.The divergent roles of growth differentiation factor-15 (GDF-15) in benign and malignant skin pathologies.Early Epithelial Restitution by Nonsteroidal Anti-Inflammatory Drug-Activated Gene 1 Counteracts Intestinal Ulcerative Injuries.Multiple mechanisms are involved in 6-gingerol-induced cell growth arrest and apoptosis in human colorectal cancer cells.Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells.Synthesis of Deuterated Benzopyran Derivatives as Selective COX-2 Inhibitors with Improved Pharmacokinetic Properties.
P2860
Q27010314-7BD9B097-FF55-4E2E-A4DA-7622F0430AE3Q28114786-0A0CDBC6-570F-4753-8E21-AAC466FD20C4Q28482454-D7BBD066-FCF2-4F1B-BF31-AC3A2E7371C0Q31120253-C4EFE752-0E07-4FA1-B4E8-932600BEB619Q33759704-989D8967-FBE5-4432-9D9B-C28C126B9889Q34332568-A1F54284-55AA-49B9-B426-2331B5875742Q34614124-5BF7C6C5-0B2E-4E4A-B8D3-09A132B3901AQ35098017-8B2F3E88-B70A-4D93-97AF-FCB52678EEEAQ35569185-571294AF-852E-4F7D-8AE8-57F03618122AQ35728009-0D1A3B09-978A-45EA-9DD5-4D158371AF8BQ36320215-E370D375-261F-4A54-838D-CFB523ED32C0Q36499656-A597D960-0F28-476A-A3E3-732333BF4EC9Q36572139-E86A0038-9889-4B70-B646-404C1E36A689Q36572406-FEC4B14E-A6AC-4844-A51B-0A8DAE2B4A8BQ36635900-3788A202-1401-4758-BDB7-94C29F221DC0Q36635956-7641880C-DE89-479A-9E3F-5993E3BB8F99Q36744694-EFCA5665-7CCB-44AE-B41B-A3068F2E150FQ36869509-FA2C504F-BCF0-49C4-8F36-D8E105F2C94AQ36952188-CC07B994-129E-41DD-A105-14810FD7D62CQ36981029-7B3F30F3-87BF-47FB-83BE-3F15DF7E404DQ37036925-6AF28A72-6977-44D4-AF74-196E5C2E0519Q37098082-45A51E56-9CAC-4A73-9E4C-7DD3BCBD7BD4Q37230433-78F0E031-4D9C-4A8D-914A-B225E17D9851Q37384568-B7BF79DA-81D7-4C82-99CB-C139E6EBCEE9Q37411797-691E6772-07DD-4BE7-A310-9E83E40FD8C0Q37673210-50CDFA66-7D5E-4D3E-8220-439A2DBE5698Q37833132-CDE80196-D7C1-4833-8C20-C0EDC4C354E6Q38183889-6395FF1B-2381-44BE-B305-FF7DED880002Q38358925-9F8DED4D-0F3A-45D2-A018-947B38BA62FBQ38412532-5562CA02-6CCB-4E08-ABE2-1B9D0E3089FAQ39227845-7F346887-6C79-4A6C-B9CD-BBFA5E59B8C2Q40184776-ED79C00C-4D0F-418A-A0D5-8145C5AC7EDEQ42259164-30A062D0-F593-4E90-A10E-54457769D91D
P2860
Changes in gene expression contribute to cancer prevention by COX inhibitors.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Changes in gene expression contribute to cancer prevention by COX inhibitors.
@ast
Changes in gene expression contribute to cancer prevention by COX inhibitors.
@en
type
label
Changes in gene expression contribute to cancer prevention by COX inhibitors.
@ast
Changes in gene expression contribute to cancer prevention by COX inhibitors.
@en
prefLabel
Changes in gene expression contribute to cancer prevention by COX inhibitors.
@ast
Changes in gene expression contribute to cancer prevention by COX inhibitors.
@en
P1476
Changes in gene expression contribute to cancer prevention by COX inhibitors
@en
P2093
Thomas E Eling
P356
10.1016/J.PLIPRES.2005.10.001
P577
2005-11-21T00:00:00Z